Home

Rijetko Biljka Vozi van median os Gradski cvijet kampanja upasti

Median OS vs Hazard Ratio | Stivarga Global Website
Median OS vs Hazard Ratio | Stivarga Global Website

Median Survival Time - an overview | ScienceDirect Topics
Median Survival Time - an overview | ScienceDirect Topics

Novel models for prediction of benefit and toxicity with FOLFIRINOX  treatment of pancreatic cancer using clinically available parameters | PLOS  ONE
Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters | PLOS ONE

Effectiveness & Safety of TECENTRIQ® (atezolizumab) for ES-SCLC
Effectiveness & Safety of TECENTRIQ® (atezolizumab) for ES-SCLC

Overall survival. Median OS was 13 months (95%Cl 9–16). | Download  Scientific Diagram
Overall survival. Median OS was 13 months (95%Cl 9–16). | Download Scientific Diagram

Avastin® (bevacizumab) Clinical Trials | CC Treatment
Avastin® (bevacizumab) Clinical Trials | CC Treatment

KarMMa Survival Rates | ABECMA® (idecabtagene vicleucel)
KarMMa Survival Rates | ABECMA® (idecabtagene vicleucel)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall  survival in patients with advanced melanoma treated with nivolumab |  Journal for ImmunoTherapy of Cancer | Full Text
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab | Journal for ImmunoTherapy of Cancer | Full Text

Efficacy Data | Xofigo® (Radium Ra 223 Dichloride)
Efficacy Data | Xofigo® (Radium Ra 223 Dichloride)

Efficacy I PLUVICTO
Efficacy I PLUVICTO

Cemiplimab prolongs OS in NSCLC with high PD-L1 expression
Cemiplimab prolongs OS in NSCLC with high PD-L1 expression

Comparison of median OS (overall survival) and PFS (progression free... |  Download Scientific Diagram
Comparison of median OS (overall survival) and PFS (progression free... | Download Scientific Diagram

Pembrolizumab regimen confers substantial survival benefit in untreated  metastatic nonsquamous NSCLC
Pembrolizumab regimen confers substantial survival benefit in untreated metastatic nonsquamous NSCLC

KarMMa Survival Rates | ABECMA® (idecabtagene vicleucel)
KarMMa Survival Rates | ABECMA® (idecabtagene vicleucel)

Overall survival of patients with metastatic breast cancer in Sweden: a  nationwide study | British Journal of Cancer
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer

BLINCYTO® Adult Efficacy | BLINCYTO® (blinatumomab)
BLINCYTO® Adult Efficacy | BLINCYTO® (blinatumomab)

Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of  momelotinib in patients with myelofibrosis | Leukemia
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia

Kaplan-Meier curves for overall survival. The median overall survival... |  Download Scientific Diagram
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram

A Overall survival (OS) for the entire cohort. The median OS is... |  Download Scientific Diagram
A Overall survival (OS) for the entire cohort. The median OS is... | Download Scientific Diagram

Overall survival of patients with metastatic breast cancer in Sweden: a  nationwide study | British Journal of Cancer
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer

Avastin® (bevacizumab) Clinical Trials | NSCLC Treatment
Avastin® (bevacizumab) Clinical Trials | NSCLC Treatment

Median progression-free survival (PFS), duration of response (DOR), and...  | Download Scientific Diagram
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram

Kaplan-Meier plots for survivals. In Figure 2A, a median OS of 9.1... |  Download Scientific Diagram
Kaplan-Meier plots for survivals. In Figure 2A, a median OS of 9.1... | Download Scientific Diagram

Median overall survival (mOS) and median progression-free survival... |  Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram

Efficacy Data in Metastatic Colorectal Carcinoma | STIVARGA® (regorafenib)  Global HCP Website
Efficacy Data in Metastatic Colorectal Carcinoma | STIVARGA® (regorafenib) Global HCP Website